Sage Therapeutics Inc’s recent filing unveils that its Officer JONAS JEFFREY M acquired Company’s shares for reported $41441.0 on Dec 10 ’24. In the deal valued at $5.53 per share,7,500 shares were bought.
A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in late November from “an Underperform” to “a Sector perform”. RBC Capital Mkts revised its rating on October 04, 2024. It rated SAGE as “a Sector perform” which previously was an “an Outperform”.
Price Performance Review of SAGE
On Friday, Sage Therapeutics Inc [NASDAQ:SAGE] saw its stock fall -2.41% to $7.30. Over the last five days, the stock has lost -6.29%. Sage Therapeutics Inc shares have risen nearly 34.44% since the year began. Nevertheless, the stocks have fallen -47.63% over the past one year. While a 52-week high of $14.31 was reached on 03/28/25, a 52-week low of $4.62 was recorded on 01/02/25. SMA at 50 days reached $7.57, while 200 days put it at $7.31.
Levels Of Support And Resistance For SAGE Stock
The 24-hour chart illustrates a support level at 7.16, which if violated will result in even more drops to 7.02. On the upside, there is a resistance level at 7.53. A further resistance level may holdings at 7.76. The Relative Strength Index (RSI) on the 14-day chart is 45.37, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.18, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.08%. Stochastics %K at 36.94% indicates the stock is a holding.
How much short interest is there in Sage Therapeutics Inc?
A steep rise in short interest was recorded in Sage Therapeutics Inc stocks on 2025-04-15, growing by 0.1 million shares to a total of 4.36 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 4.26 million shares. There was a rise of 2.38%, which implies that there is a positive sentiment for the stock.
